NASDAQ : TENX
Tenax Therapeutics, Inc. — Financial statements
Healthcare · Biotechnology · United States
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 23.36M | 23.71M | 6.79M | 5.00M | 5.68M | 6.38M |
| Research & Development | 45.26M | 32.67M | 12.71M | 3.23M | 5.38M | 25.15M |
| Operating Expenses | 68.61M | 56.38M | 19.49M | 8.23M | 11.05M | 31.53M |
| Operating Income | -68.61M | -56.38M | -19.49M | -8.23M | -11.05M | -31.53M |
| Interest Expense | -23.00K | -24.00K | -4.44K | -949.00 | ||
| Interest & Investment Income | 3.78M | 3.82M | 1.91M | 484.00K | ||
| Other Non Operating Income (Expenses) | -28.00K | -33.00K | 1.00K | 63.00K | 6.29K | 17.03K |
| EBT Excluding Unusual Items | -64.86M | -52.60M | -17.60M | -7.71M | -11.05M | -31.51M |
| Gain (Loss) on Sale of Investments | -9.43K | |||||
| Gain (Loss) on Sale of Assets | 2.90K | |||||
| Other Unusual Items | -952.77K | |||||
| Pretax Income | -64.86M | -52.60M | -17.60M | -7.71M | -11.05M | -32.47M |
| Net Income | -64.86M | -52.60M | -17.60M | -7.71M | -11.05M | -32.47M |
| Net Income to Common | -64.86M | -52.60M | -17.60M | -7.71M | -11.05M | -32.47M |
| Shares Outstanding (Basic) | 44.21M | 39.22M | 15.27M | 248.45K | 18.39K | 12.86K |
| Shares Outstanding (Diluted) | 44.21M | 39.22M | 15.27M | 248.45K | 18.39K | 12.86K |
| EPS (Basic) | -1.47 | -1.34 | -1.15 | -31.04 | -600.72 | -2,525.03 |
| EPS (Diluted) | -1.47 | -1.34 | -1.15 | -31.04 | -600.72 | -2,525.03 |
| Free Cash Flow | -46.03M | -35.80M | -14.81M | -5.90M | -11.39M | -10.86M |
| Free Cash Flow Per Share | -1.04 | -0.91 | -0.97 | -23.76 | -619.37 | -844.53 |
| EBITDA | -19.49M | -8.23M | -11.05M | -31.52M | ||
| D&A For EBITDA | 8.00K | 8.00K | 5.14K | 4.12K | ||
| EBIT | -68.61M | -56.38M | -19.49M | -8.23M | -11.05M | -31.53M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 117.98M | 97.56M | 94.85M | 9.79M | 2.12M | 5.58M |
| Cash & Short-Term Investments | 117.98M | 97.56M | 94.85M | 9.79M | 2.12M | 5.58M |
| Prepaid Expenses | 3.42M | 5.64M | 1.77M | 1.64M | 738.93K | 105.08K |
| Other Current Assets | 272.00K | 1.02M | 64.00K | 252.00K | 345.86K | |
| Total Current Assets | 121.66M | 104.23M | 96.69M | 11.68M | 3.21M | 5.69M |
| Property, Plant & Equipment | 186.69K | 294.80K | ||||
| Other Long-Term Assets | 1.00K | 9.55K | 8.44K | |||
| Total Assets | 121.66M | 104.23M | 96.69M | 11.69M | 3.40M | 5.99M |
| Accounts Payable | 6.79M | 6.04M | 3.16M | 2.07M | 448.43K | 859.64K |
| Accrued Expenses | 1.28M | 1.11M | 1.54M | 1.01M | 655.65K | 597.15K |
| Short-Term Debt | 501.00K | 624.30K | ||||
| Current Portion of Leases | 119.39K | 107.19K | ||||
| Total Current Liabilities | 8.07M | 7.16M | 4.69M | 3.59M | 1.85M | 1.56M |
| Long-Term Leases | 64.20K | 183.59K | ||||
| Total Liabilities | 8.07M | 7.16M | 4.69M | 3.59M | 1.91M | 1.75M |
| Common Stock | 3.00K | 1.00K | 3.00 | 2.52K | ||
| Additional Paid-In Capital | 514.56M | 464.52M | 406.85M | 305.35M | 291.03M | 282.74M |
| Retained Earnings | -400.97M | -367.45M | -314.86M | -297.25M | -289.54M | -278.49M |
| Total Common Equity | 113.59M | 97.07M | 91.99M | 8.10M | 1.49M | 4.24M |
| Shareholders' Equity | 113.59M | 97.07M | 91.99M | 8.10M | 1.49M | 4.24M |
| Total Liabilities & Equity | 121.66M | 104.23M | 96.69M | 11.69M | 3.40M | 5.99M |
| Total Debt | 501.00K | 807.89K | 290.78K | |||
| Net Cash (Debt) | 117.98M | 97.56M | 94.85M | 9.29M | 1.32M | 5.29M |
| Net Cash Per Share | 2.67 | 2.49 | 6.21 | 37.40 | 71.55 | 411.57 |
| Filing Date Shares Outstanding | 57.28M | 50.30M | 35.85M | 1.96M | 351.22K | 15.75K |
| Total Common Shares Outstanding | 51.81M | 42.42M | 35.30M | 298.28K | 28.65K | 15.75K |
| Working Capital | 113.59M | 97.07M | 91.99M | 8.10M | 1.36M | 4.13M |
| Book Value Per Share | 2.19 | 2.29 | 2.61 | 27.15 | 52.11 | 269.43 |
| Tangible Book Value | 113.59M | 97.07M | 91.99M | 8.10M | 1.49M | 4.24M |
| Tangible Book Value Per Share | 2.19 | 2.29 | 2.61 | 27.15 | 52.11 | 269.43 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -64.86M | -52.60M | -17.60M | -7.71M | -11.05M | -32.47M |
| Depreciation & Amortization | 8.00K | 113.33K | 108.98K | |||
| Loss (Gain) From Sale of Assets | 1.00K | -2.90K | ||||
| Loss (Gain) From Sale of Investments | 9.43K | |||||
| Stock-Based Compensation | 16.58M | 19.16M | 1.12M | 191.00K | 365.31K | 773.79K |
| Other Operating Activities | 23.00K | 24.00K | 4.44K | 21.34M | ||
| Change in Accounts Receivable | -306.00K | -356.52K | -22.50K | |||
| Change in Accounts Payable | 6.23M | 2.88M | 1.06M | 1.65M | -344.95K | -544.59K |
| Change in Other Net Operating Assets | -3.98M | -5.25M | 581.00K | 237.00K | -119.39K | -43.00K |
| Operating Cash Flow | -46.03M | -35.80M | -14.81M | -5.90M | -11.39M | -10.86M |
| Capital Expenditures | -2.32K | -5.25K | ||||
| Sale of Property, Plant & Equipment | 3.00K | |||||
| Investment in Securities | 457.86K | |||||
| Investing Cash Flow | 3.00K | -2.32K | 452.61K | |||
| Short-Term Debt Repaid | -501.00K | -624.00K | ||||
| Total Debt Repaid | -501.00K | -624.00K | ||||
| Net Debt Issued (Repaid) | -501.00K | -624.00K | ||||
| Issuance of Common Stock | 58.54M | 15.30M | 68.00K | 1.00K | 2.06K | 544.65K |
| Other Financing Activities | 23.22M | 100.30M | 14.19M | 7.93M | 9.19M | |
| Financing Cash Flow | 58.54M | 38.51M | 99.87M | 13.57M | 7.93M | 9.74M |
| Net Cash Flow | 12.51M | 2.71M | 85.06M | 7.67M | -3.46M | -666.32K |
| Free Cash Flow | -46.03M | -35.80M | -14.81M | -5.90M | -11.39M | -10.86M |
| Free Cash Flow Per Share | -1.04 | -0.91 | -0.97 | -23.76 | -619.37 | -844.53 |
| Levered Free Cash Flow | -24.05M | -18.44M | -9.41M | -3.79M | -7.77M | -19.33M |
| Unlevered Free Cash Flow | -24.05M | -18.44M | -9.39M | -3.77M | -7.76M | -19.33M |
| Cash Interest Paid | 23.00K | |||||
| Change in Working Capital | 2.25M | -2.36M | 1.64M | 1.58M | -820.86K | -610.09K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 103.11M | 494.55M | 218.45M | 6.55M | 4.98M | 26.21M |
| Enterprise Value | -14.87M | 395.18M | 120.14M | -4.41M | 1.38M | 18.18M |
| Last Close Price | 1.80 | 12.19 | 6.19 | 21.97 | 178.24 | 1,664.00 |
| PB Ratio | 0.82 | 5.09 | 2.38 | 0.81 | 3.34 | 6.18 |
| P/TBV Ratio | 0.91 | 5.09 | 2.38 | 0.81 | 3.34 | 6.18 |
| Debt / Equity Ratio | 0.06 | 0.54 | 0.07 | |||
| Net Debt / Equity Ratio | -1.04 | -1.00 | -1.03 | -1.15 | -0.88 | -1.25 |
| Net Debt / EBITDA Ratio | 4.87 | 1.13 | 0.12 | 0.17 | ||
| Net Debt / FCF Ratio | 2.56 | 2.73 | 6.40 | 1.57 | 0.12 | 0.49 |
| Quick Ratio | 14.61 | 13.63 | 20.21 | 2.73 | 1.15 | 3.57 |
| Current Ratio | 15.07 | 14.56 | 20.60 | 3.26 | 1.74 | 3.64 |
| Return on Equity (ROE) | -59.80% | -55.64% | -35.17% | -160.80% | -385.12% | -732.21% |
| Return on Assets (ROA) | -37.70% | -35.08% | -22.48% | -68.21% | -147.02% | -306.43% |
| Return on Capital Employed (ROCE) | -60.40% | -58.10% | -21.20% | -101.70% | -709.90% | -712.00% |
| Earnings Yield | -81.52% | -10.64% | -8.06% | -117.68% | -221.89% | -123.88% |
| FCF Yield | -44.64% | -7.24% | -6.78% | -90.10% | -228.78% | -41.43% |
| Buyback Yield / Dilution | -31.87% | -156.80% | -6,046.87% | -1,250.92% | -43.00% |